These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 7778884

  • 1. Angiotensin-converting enzyme inhibition and ventricular remodeling after myocardial infarction.
    Pfeffer JM, Fischer TA, Pfeffer MA.
    Annu Rev Physiol; 1995; 57():805-26. PubMed ID: 7778884
    [No Abstract] [Full Text] [Related]

  • 2. The renin-angiotensin system in the heart and vascular wall: new therapeutic aspects.
    Falkenhahn M, Gohlke P, Paul M, Stoll M, Unger T.
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S6-13. PubMed ID: 7898096
    [Abstract] [Full Text] [Related]

  • 3. Left ventricular remodeling after myocardial infarction: does the cardiac renin-angiotensin system play a role?
    Lindpaintner K, Niedermaier N, Drexler H, Ganten D.
    J Cardiovasc Pharmacol; 1992; 20 Suppl 1():S41-7. PubMed ID: 1380618
    [Abstract] [Full Text] [Related]

  • 4. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
    Duncan AM, James GM, Anastasopoulos F, Kladis A, Briscoe TA, Campbell DJ.
    J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin-converting enzyme inhibition limits dysfunction in adjacent noninfarcted regions during left ventricular remodeling.
    Kramer CM, Ferrari VA, Rogers WJ, Theobald TM, Nance ML, Axel L, Reichek N.
    J Am Coll Cardiol; 1996 Jan; 27(1):211-7. PubMed ID: 8522697
    [Abstract] [Full Text] [Related]

  • 6. Left ventricular remodeling following myocardial infarction.
    Pfeffer MA.
    Cardiologia; 1994 Dec; 39(12 Suppl 1):25-6. PubMed ID: 7634276
    [No Abstract] [Full Text] [Related]

  • 7. Tissue angiotensin II and myocardial infarction.
    Sun Y, Weber KT.
    EXS; 1996 Dec; 76():479-88. PubMed ID: 8805813
    [No Abstract] [Full Text] [Related]

  • 8. The renin-angiotensin system as a target for therapeutic intervention.
    Swales JD.
    J Cardiovasc Pharmacol; 1994 Dec; 24 Suppl 2():S1-5. PubMed ID: 7898088
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of matrix metalloproteinase-9 activity by lisinopril after myocardial infarction in hamsters.
    Takai S, Yamamoto D, Jin D, Inagaki S, Yoshikawa K, Tanaka K, Miyazaki M.
    Eur J Pharmacol; 2007 Jul 30; 568(1-3):231-3. PubMed ID: 17512521
    [Abstract] [Full Text] [Related]

  • 10. Effect of ACE inhibition on myocardial ischaemia.
    Ferrari R.
    Eur Heart J; 1998 Sep 30; 19 Suppl J():J30-5. PubMed ID: 9796838
    [Abstract] [Full Text] [Related]

  • 11. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
    Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM.
    Clin Sci (Lond); 2012 Dec 30; 123(11):649-58. PubMed ID: 22715807
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin-converting enzyme inhibition and salt in experimental myocardial infarction.
    Yoshida K, Kohzuki M, Casley DJ, Johnston CI.
    J Cardiovasc Pharmacol; 1998 Sep 30; 32(3):357-65. PubMed ID: 9733347
    [Abstract] [Full Text] [Related]

  • 13. [ACE-inhibitors after infarction: current knowledge and future prospects].
    Penco M, Romano S, Fedele F, Dagianti A.
    Cardiologia; 1994 Dec 30; 39(12 Suppl 1):191-6. PubMed ID: 7634266
    [Abstract] [Full Text] [Related]

  • 14. Ventricular remodeling and angiotensin-converting enzyme inhibitors.
    Goldstein S, Sabbah H.
    J Cardiovasc Pharmacol; 1994 Dec 30; 24 Suppl 3():S27-31. PubMed ID: 7700061
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin converting enzyme inhibition therapy following myocardial infarction. Rationale for clinical trials.
    Pfeffer MA.
    Herz; 1991 Sep 30; 16 Spec No 1():278-82. PubMed ID: 1840297
    [Abstract] [Full Text] [Related]

  • 16. [Growth stimulating properties of angiotensin II on the heart: consequences for therapy of heart failure].
    Schunkert H, Holmer SR, Riegger G.
    Z Kardiol; 1993 Sep 30; 82 Suppl 4():1-6. PubMed ID: 8147057
    [Abstract] [Full Text] [Related]

  • 17. Angiotensin-converting enzyme inhibition: prospects for the future.
    Jackson B, Mendelsohn FA, Johnston CI.
    J Cardiovasc Pharmacol; 1991 Sep 30; 18 Suppl 7():S4-8. PubMed ID: 1725200
    [Abstract] [Full Text] [Related]

  • 18. Bradykinin and cardiac protection.
    Gohlke P, Tschöpe C, Unger T.
    Adv Exp Med Biol; 1997 Sep 30; 432():159-72. PubMed ID: 9433522
    [No Abstract] [Full Text] [Related]

  • 19. The role of angiotensin-converting enzyme inhibitors in reducing ventricular remodeling after myocardial infarction.
    Fara AM.
    J Cardiovasc Nurs; 1993 Oct 30; 8(1):32-48. PubMed ID: 8106896
    [Abstract] [Full Text] [Related]

  • 20. The use of angiotensin-converting enzyme inhibitors after acute myocardial infarction.
    Mehra IV, Wilson MD.
    Pharmacotherapy; 1993 Oct 30; 13(5):440-6. PubMed ID: 8247909
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.